US 11,730,796 B2
Transfected t-cells and t-cell receptors for use in immunotherapy against cancers
Dominik Maurer, Moessingen (DE); Leonie Alten, Tuebingen (DE); and Sebastian Bunk, Tuebingen (DE)
Assigned to IMMATICS BIOTECHNOLOGIES GMBH, Tuebingen (DE)
Filed by Immatics Biotechnologies GmbH, Tuebingen (DE)
Filed on Feb. 26, 2020, as Appl. No. 16/802,431.
Application 16/802,431 is a division of application No. 16/413,939, filed on May 16, 2019, granted, now 10,596,242.
Application 16/413,939 is a continuation of application No. 15/461,020, filed on Mar. 16, 2017, granted, now 10,537,624, issued on Jan. 21, 2020.
Claims priority of provisional application 62/308,970, filed on Mar. 16, 2016.
Claims priority of application No. 1604494 (GB), filed on Mar. 16, 2016.
Prior Publication US 2020/0188497 A1, Jun. 18, 2020
Int. Cl. C07K 14/725 (2006.01); A61K 39/00 (2006.01); A61K 45/06 (2006.01); C07K 14/74 (2006.01); G01N 33/574 (2006.01); C12N 5/0783 (2010.01)
CPC A61K 39/0011 (2013.01) [A61K 45/06 (2013.01); C07K 14/7051 (2013.01); C07K 14/70539 (2013.01); C12N 5/0636 (2013.01); G01N 33/574 (2013.01); A61K 2039/5158 (2013.01); C07K 2319/00 (2013.01); C07K 2319/03 (2013.01); C07K 2319/55 (2013.01); C07K 2319/60 (2013.01)] 24 Claims
 
1. A nucleic acid or nucleic acids encoding an alpha chain and a beta chain,
wherein the alpha chain comprises
SEQ ID NO: 5,
SEQ ID NO: 6,
SEQ ID NO: 7, and
the beta chain comprises
SEQ ID NO: 13,
SEQ ID NO: 14, and
SEQ ID NO: 15.